ライフサイエンスコーパス: trandolapril

1 randolapril, ARBs vs. quinapril, or ARBs vs. trandolapril).

2 the angiotensin-converting enzyme inhibitor trandolapril.

3 chlorothiazide; and 4113 (52.4%) were taking trandolapril.

4 concise enantioselective formal synthesis of trandolapril.

5 Trandolapril and hydrochlorothiazide were used as added

6 Trandolapril and/or hydrochlorothiazide was administered

7 ison (i.e., ACEIs vs. ARBs vs. quinapril vs. trandolapril) and (P 0.0007) for pairwise comparison (i.

8 sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochloroth

9 arison (i.e., ACEIs vs. quinapril, ACEIs vs. trandolapril, ARBs vs. quinapril, or ARBs vs. trandolapr

10 nts were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 pati

11 The verapamil-trandolapril-based strategy was as clinically effective

12 nificantly after 12 months of treatment with trandolapril compared with placebo.

13 nt differences associated with quinapril and trandolapril, compared to other ACEIs and ARBs.

14 Although trandolapril did not improve survival in the overall PEA

15 nt in the placebo group (hazard ratio in the trandolapril group, 0.96; 95 percent confidence interval

16 y revascularization--was 21.9 percent in the trandolapril group, as compared with 22.5 percent in the

17 e ACEI antihypertensive class (quinapril and trandolapril) have a significantly higher cluster of pul

18 thiazide or verapamil-SR (sustained release)/trandolapril in INVEST (INternational VErapamil SR Trand

19 The ACE inhibitor trandolapril may improve peripheral neuropathy in normot

20 ons between hs-CRP levels and the effects of trandolapril on any of the above outcomes.

21 eserved systolic function were randomized to trandolapril or placebo and followed up for a median of

22 lar ejection fraction who were randomized to trandolapril or placebo as part of the Prevention of Eve

23 ,627 patients with SIHD randomly assigned to trandolapril or placebo within the PEACE (Prevention of

24 ort, in which mean eGFR was relatively high, trandolapril reduced mortality in patients with reduced

25 tients in the top quartile of FGF-23 levels, trandolapril significantly reduced cardiovascular death

26 Trandolapril significantly reduced the risk of cardiovas

27 The INternational VErapamil-trandolapril STudy (INVEST) compared outcomes in hyperte

28 0 patients of the International Verapamil SR/Trandolapril Study (INVEST) Genetic Substudy (INVEST-GEN

29 objective of the International Verapamil SR/Trandolapril Study (INVEST) is to compare the risk for a

30 US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial

31 sis of data from the International Verapamil-Trandolapril Study (INVEST), which was conducted from Se

32 rticipants in the International Verapamil SR-Trandolapril Study (INVEST).

33 lapril in INVEST (INternational VErapamil SR Trandolapril STudy) were categorized into 3 groups on th

34 s (n=8290) were randomly assigned to receive trandolapril (target, 4 mg/d) or placebo.

35 The effect of trandolapril therapy on outcomes was not modified signif

36 Nevertheless, trandolapril therapy was associated with a significantly

37 Lower follow-up BP and addition of trandolapril to verapamil SR each were associated with r

38 antagonist (sustained-release verapamil plus trandolapril) vs B-blocker (atenolol plus hydrochlorothi

39 Trandolapril was also recommended for patients with hear

40 Trandolapril was associated with a reduction in total mo

41 Specifically, quinapril and trandolapril were found to have a statistically signific

42 r blockade (candesartan) and ACE inhibition (trandolapril) were also tested in LTM.

43 0 mm Hg (HRs 0.82 or 0.70, respectively) and trandolapril with verapamil SR (HRs 0.78 and 0.79) were